Last Updated April 2020

Bibliography

* Note: First author a trainee: Faculty Member, Subspecialty Resident (Fellow), Resident, or Medical Student.

Refereed Papers/Articles

Original Research

1. Clark RH, Sousa J, Laughon MM, Tolia VN. Gastroschisis prevalence substantially decreased from 2009 through 2018 after a 3-fold increase from 1997 to 2008. J Pediatr Surg. 2020 Mar 24.
2. Jackson W*, Taylor G, Bamat NA, Zimmerman K, Clark R, Benjamin DK, Laughon MM, Greenberg RG, Hornik CP. Outcomes associated with surfactant in more mature and larger premature infants with respiratory distress syndrome.J Perinatol. 2020 Feb 20.
3. Ji D, Smith PB, Clark RH, Zimmerman KO, Laughon M, Ku L, Greenberg RG. Wide variation in caffeine discontinuation timing in premature infants. J Perinatol. 2020 Feb;40(2):288-293.
4. Zimmerman KO*, Wu H, Laughon M, Greenberg RG, Walczak R, Schulman SR, Smith PB, Hornik CP, Cohen-Wolkowiez M, Watt KM. Dexmedetomidine Pharmacokinetics and a New Dosing Paradigm in Infants Supported With Cardiopulmonary Bypass. Anesth Analg. 2019 Dec;129(6):1519-1528.
5. Thébaud B, Goss KN, Laughon M, Whitsett JA, Abman SH, Steinhorn RH, Aschner JL, Davis PG, McGrath-Morrow SA, Soll RF, Jobe AH. Bronchopulmonary dysplasia. Nat Rev Dis Primers. 2019 Nov 14;5(1):78.
6. Thompson EJ*, Wu H, Melloni C, Balevic S, Sullivan JE, Laughon M, Clark KM, Kalra R, Mendley S, Payne EH, Erinjeri J, Gelber CE, Harper B, Cohen-Wolkowiez M, Hornik CP; Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee. Population Pharmacokinetics of Doxycycline in Children. Antimicrob Agents Chemother. 2019 Sep 23.
7. Gonski S*, Hupp SR, Cotten CM, Clark RH, Laughon M, Watt K, Hornik CP, Kumar K, Smith PB, Greenberg RG. Risk of development of treated retinopathy of prematurity in very low birth weight infants. J Perinatol. 2019 Sep 6
8. Gonzalez D*, Laughon MM, Smith PB, Ge S, Ambalavanan N, Atz A, Sokol GM, Hornik CD, Stewart D, Mundakel G, Poindexter BB, Gaedigk R, Mills M, Cohen-Wolkowiez M, Martz K, Hornik CP; Best Pharmaceuticals for Children Act - Pediatric Trials Network Steering Committee. Population Pharmacokinetics of Sildenafil in Extremely Premature Infants. Br J Clin Pharmacol. 2019 Sep 2
9. Bamat NA, Kirpalani H, Feudtner C, Jensen EA, Laughon MM, Zhang H, Monk HM, Passarella M, Lorch SA. Medication use in infants with severe bronchopulmonary dysplasia admitted to United States children's hospitals. J Perinatol. 2019 Jun 21.
10. Puia-Dumitrescu M*, Smith PB, Zhao J, Soriano A, Payne EH, Harper B, Bendel-Stenzel E, Moya F, Chhabra R, Ku L, Laughon M, Wade KC; Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee. Dosing and Safety of Off-label Use of Caffeine Citrate in Premature Infants. J Pediatr. 2019 May 14.
11. Hornik CP, Atz AM, Bendel C, Chan F, Downes K, Grundmeier R, Fogel B, Gipson D, Laughon M, Miller M, Smith M, Livingston C, Kluchar C, Heath A, Jarrett C, McKerlie B, Patel H, Hunter C; Best Pharmaceuticals for Children Act–Pediatric Trials Network. Creation of a Multicenter Pediatric Inpatient Data Repository Derived from Electronic Health Records. Appl Clin Inform. 2019 Mar;10(2):307-315.
12. Jensen EA, Dysart K, Gantz MG, McDonald S, Bamat NA, Keszler M, Kirpalani H, Laughon MM, Poindexter BB, Duncan AF, Yoder BA, Eichenwald E, DeMauro SB; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. The Diagnosis of Bronchopulmonary Dysplasia in Very Preterm Infants: An Evidence-Based Approach. Am J Respir Crit Care Med. 2019 Apr 17.
13. Smith PB, Cotten CM, Hudak ML, Sullivan JE, Poindexter BB, Cohen-Wolkowiez M, Boakye-Agyeman F, Lewandowski A, Anand R, Benjamin DK Jr, Laughon MM; Best Pharmaceuticals for Children Act—

Pediatric Trials Network Steering Committee. Rifampin Pharmacokinetics and Safety in Preterm and Term Infants. Antimicrob Agents Chemother. 2019 May 24;63(6)

14. Venkatesh KK*, Jackson W, Hughes BL, Laughon MM, Thorp JM, Stamilio DM. Association of chorioamnionitis and its duration with neonatal morbidity and mortality. J Perinatol. 2019 Feb 5.

15. Watt KM, Hornik CP, Balevic SJ, Mundakel G, Cotten CM, Harper B, Benjamin DK, Anand R, Laughon M, Smith PB, Cohen-Wolkowiez M; Best Pharmaceuticals for Children Act - Pediatric Trials Network Steering Committee. Pharmacokinetics of ticarcillin-clavulanate in premature infants. Br J Clin Pharmacol. 2019 Feb 2.

16. Taylor G*, Jackson W, Hornik CP, Koss A, Mantena S, Homsley K, Gattis B, Kudumu-Clavell M, Clark R, Smith PB, Laughon MM. Surfactant Administration in Preterm Infants: Drug Development Opportunities.J Pediatr. 2018 Dec 21.

17. Tolia VN, Bahr TM, Bennett MM, Martin G, Greenberg RG, Laughon MM, Clark RH. The Association of Hydrocortisone Dosage on Mortality in Infants Born Extremely Premature. J Pediatr. 2018 Dec 21.

18. Greenberg RG, Gayam S, Savage D, Tong A, Gorham D, Sholomon A, Clark RH, Benjamin DK, Laughon M, Smith PB; Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee. Furosemide Exposure and Prevention of Bronchopulmonary Dysplasia in Premature Infants. J Pediatr. 2018 Dec 20.

19. Jackson W*, Taylor G, Selewski D, Smith PB, Tolleson-Rinehart S, Laughon MM. Association between furosemide in premature infants and sensorineural hearing loss and nephrocalcinosis: a systematic review. Matern Health Neonatol Perinatol. 2018 Nov 19;4:23.

20. McCrary AW*, Barker PCA, Torok RD, Spears TG, Li JS, Hornik CP, Laughon MM. Agreement of an echocardiogram-based diagnosis of pulmonary hypertension in infants at risk for bronchopulmonary dysplasia among masked reviewers. J Perinatol. 2019 Feb;39(2):248-255.

21. Hanvey IB*, Aliaga S, Laughon MM, Testoni D, Smith PB, Bauserman M. Trial Characteristics That Affect Parental Consent in Neonatal Drug Trials. Am J Perinatol. 2018 Oct 31.

22. Phelps DL, Watterberg KL, Nolen TL, Cole CA, Cotten CM, Oh W, Poindexter BB, Zaterka-Baxter KM, Das A, Lacy CB, Scorsone AM, Walsh MC, Bell EF, Kennedy KA, Schibler K, Sokol GM, Laughon MM, Lakshminrusimha S, Truog WE, Garg M, Carlo WA, Laptook AR, Van Meurs KP, Carlton DP, Graf A, DeMauro SB, Brion LP, Shankaran S, Orge FH, Olson RJ, Mintz-Hittner H, Yang MB, Haider KM, Wallace DK, Chung M, Hug D, Tsui I, Cogen MS, Donahue JP, Gaynon M, Hutchinson AK, Bremer DL, Quinn G, He YG, Lucas WR Jr, Winter TW, Kicklighter SD, Kumar K, Chess PR, Colaizy TT, Hibbs AM, Ambalavanan N, Harmon HM, McGowan EC, Higgins RD; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Effects of Myo-inositol on Type 1 Retinopathy of Prematurity Among Preterm Infants <28 Weeks' Gestational Age: A Randomized Clinical Trial. JAMA. 2018 Oct 23;320(16):1649-1658.

23. Wang LA*, Smith PB, Laughon M, Goldberg RN, Ku LC, Zimmerman KO, Balevic S, Clark RH, Benjamin DK, Greenberg RG; Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee. Prolonged furosemide exposure and risk of abnormal newborn hearing screen in premature infants. Early Hum Dev. 2018 Oct;125:26-30.

24. Kumar KR*, Clark DA, Kim EM, Perry JD, Wright K, Thomas SA, Thompson EJ, Greenberg RG, Smith PB, Benjamin DK Jr, Laughon MM, Clark RH, Hornik CP. Association of Atrial Septal Defects and Bronchopulmonary Dysplasia in Premature Infants. J Pediatr. 2018 Aug 29.

25. Jackson WM*, O'Shea TM, Allred EN, Laughon MM, Gower WA, Leviton A. Risk factors for chronic lung disease and asthma differ among children born extremely preterm. Pediatr Pulmonol. 2018 Nov;53(11):1533-1540.

26. Zimmerman KO*, Wu H, Laughon M, Greenberg RG, Walczak R, Schulman SR, Smith PB, Hornik CP, Cohen-Wolkowiez M, Watt KM. Dexmedetomidine Pharmacokinetics and a New Dosing Paradigm in Infants Supported With Cardiopulmonary Bypass. Anesth Analg. 2018 Aug 22.

27. Thompson EJ*, Perez K, Hornik CP, Smith PB, Clark RH, Laughon M; Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee. Sildenafil Exposure in the Neonatal Intensive Care Unit.Am J Perinatol. 2018 Aug 6.

28. Ge S, Beechinor RJ, Hornik CP, Standing JF, Zimmerman K, Cohen-Wolkowiez M, Laughon MM, Clark R, Gonzalez D. External Evaluation of a Gentamicin Infant Population Pharmacokinetic Model Using Data from a National Electronic Health Record Database. Antimicrob Agents Chemother. 2018 Jun 18.

29. Heling AZ*, Laughon MM, Price WA. Effect of Routine, Screening Head Ultrasounds on Clinical Interventions for Premature Infants. Am J Perinatol. 2018 Aug;35(10):959-963.

30. Thompson EJ*, Greenberg RG, Kumar K, Laughon M, Smith PB, Clark RH, Crowell A, Shaw L, Harrison L, Scales G, Bell N, Hornik CP. Association between Furosemide Exposure and Patent Ductus Arteriosus in Hospitalized Infants of Very Low Birth Weight. J Pediatr. 2018 Aug;199:231-236.

31. Dallefeld SH*, Atz AM, Yogev R, Sullivan JE, Al-Uzri A, Mendley SR, Laughon M, Hornik CP, Melloni C, Harper B, Lewandowski A, Mitchell J, Wu H, Green TP, Cohen-Wolkowiez M. A pharmacokinetic model for amiodarone in infants developed from an opportunistic sampling trial and published literature data. J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):419-430.

32. Le J, Poindexter B, Sullivan JE, Laughon M, Delmore P, Blackford M, Yogev R, James LP, Melloni C, Harper B, Mitchell J, Benjamin DK Jr, Boakye-Agyeman F, Cohen-Wolkowiez M. Comparative Analysis of Ampicillin Plasma and Dried Blood Spot Pharmacokinetics in Neonates. Ther Drug Monit. 2018 Feb;40(1):103-108.

33. Hornik CP, Onufrak NJ, Smith PB, Cohen-Wolkowiez M, Laughon MM, Clark RH, Gonzalez D. Association between oral sildenafil dosing, predicted exposure, and systemic hypotension in hospitalised infants. Cardiol Young. 2018 Jan;28(1):85-92.

34. Steinhorn R, Davis JM, Göpel W, Jobe A, Abman S, Laughon M, Bancalari E, Aschner J, Ballard R, Greenough A, Storari L, Thomson M, Ariagno RL, Fabbri L, Turner MA; International Neonatal Consortium. Chronic Pulmonary Insufficiency of Prematurity: Developing Optimal Endpoints for Drug Development. J Pediatr. 2017 Dec;191:15-21.e1.

35. Schueller M, Greenberg RG, Smith PB, Laughon MM, Clark RH, Hornik CP. In-Hospital Outcomes Following Extracorporeal Membrane Oxygenation in a Retrospective Cohort of Infants. Am J Perinatol. 2017 Nov;34(13):1347-1353.

36. Thompson EJ*, Greenberg RG, Kumar K, Laughon M, Smith PB, Clark RH, Crowell A, Shaw L, Harrison L, Scales G, Bell N, Hornik CP. Association between Furosemide Exposure and Patent Ductus Arteriosus in Hospitalized Infants of Very Low Birth Weight. J Pediatr. 2018 May 8.

37. Salerno SN*, Bernhardt J, Laughon M, Jhaveri R, Massaro M, Gonzalez D. Pharmacokinetics of Ceftaroline in a Preterm Infant With Methicillin-Resistant Staphylococcus Aureus Pneumonia. J Pediatric Infect Dis Soc. 2017 Oct 16.

38. Lee JH, Greenberg RG, Quek BH, Clark RH, Laughon MM, Smith PB, Hornik CP. Association between early echocardiography, therapy for patent ductus arteriosus, and outcomes in very low birth weight infants. Cardiol Young. 2017 Nov;27(9):1732-1739.

39. Shah M, Phillips MR, Klein M, Marzinsky A, Rice C, Laughon M, Lee S. A Single Institution Study of Umbilical Vein Complications and Necrotizing Enterocolitis in Premature Infants. Am Surg. 2017 Sep 1;83(9):364-366.

40. Jensen EA*, Dysart KC, Gantz MG, Carper B, Higgins RD, Keszler M, Laughon MM, Poindexter BB, Stoll BJ, Walsh MC, Schmidt B; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network.. Association between Use of Prophylactic Indomethacin and the Risk for Bronchopulmonary Dysplasia in Extremely Preterm Infants. J Pediatr. 2017 July; 34-40.

41. Jackson W*, Hornik CP, Messina JA, Guglielmo K, Watwe A, Delancy G, Valdez A, MacArthur T, Peter-Wohl S, Smith PB, Tolia VN, Laughon MM. In-hospital outcomes of premature infants with severe bronchopulmonary dysplasia. J Perinatol. 2017 July; 37(7):853-856.

42. Downey LC*, Cotten CM, Hornik CP, Laughon MM, Tolia VN, Clark RH, Smith PB. Association of in utero magnesium exposure and spontaneous intestinal perforations in extremely low birth weight infants. J Perinatol. 2017 Jan 26.

43. Schueller M, Greenberg RG, Smith PB, Laughon MM, Clark RH, Hornik CP. In-Hospital Outcomes Following Extracorporeal Membrane Oxygenation in a Retrospective Cohort of Infants. Am J Perinatol. 2017 May 25.

44. Greenberg RG*, Wu H, Laughon M, Capparelli E, Rowe S, Zimmerman KO, Smith PB, Cohen-Wolkowiez M. Population Pharmacokinetics of Dexmedetomidine in Infants. J Clin Pharmacol. 2017 Apr 25.

45. Hornik CP, Onufrak NJ, Smith PB, Cohen-Wolkowiez M, Laughon MM, Clark RH, Gonzalez D. Association between oral sildenafil dosing, predicted exposure, and systemic hypotension in hospitalised infants. Cardiol Young. 2017 Aug 8:1-8.

46. Virkud YV*, Hornik CP, Benjamin DK, Laughon MM, Clark RH, Greenberg RG, Smith PB. Respiratory Support for Very Low Birth Weight Infants Receiving Dexamethasone. J Pediatr. 2017 Jan 18.

47. Lemyre B, Laughon M, Bose C, Davis PG. Early nasal intermittent positive pressure ventilation (NIPPV) versus early nasal continuous positive airway pressure (NCPAP) for preterm infants. Cochrane Database Syst Rev. 2016 Dec 15.

48. Zimmerman KO*, Smith PB, Benjamin DK, Laughon M, Clark R, Traube C, Stürmer T, Hornik CP. Sedation, Analgesia, and Paralysis during Mechanical Ventilation of Premature Infants. J Pediatr. 2017 Jan;180:99-104.

49. Allman R, Sousa J, Walker MW, Laughon MM, Spitzer AR, Clark RH. The epidemiology, prevalence and hospital outcomes of infants with gastroschisis. J Perinatol. 2016 Oct;36(10):901-5.

50. Thakkar N*, Gonzalez D, Cohen-Wolkowiez M, Massaro MM, Bernhardt J, Zane NR, Laughon MM. An opportunistic study evaluating pharmacokinetics of sildenafil for the treatment of pulmonary hypertension in infants. J Perinatol. 2016 Sep;36(9):744-7.

51. Momper JD, Capparelli EV, Wade KC, Kantak A, Dhanireddy R, Cummings JJ, Nedrelow JH, Hudak ML, Mundakel GT, Natarajan G, Gao J, Laughon M, Smith PB, Benjamin DK Jr. Population Pharmacokinetics of Fluconazole in Premature Infants with Birth Weights Less than 750 Grams. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5539-45.

52. Zimmerman KO*, Smith PB, Benjamin DK, Laughon M, Clark R, Traube C, Stürmer T, Hornik CP. Sedation, Analgesia, and Paralysis during Mechanical Ventilation of Premature Infants. J Pediatr. 2016 Aug 10.

53. Aliaga S, Zhang J, Long DL, Herring AH, Laughon M, Boggess K, Reddy UM, Grantz KL. Center Variation in the Delivery of Indicated Late Preterm Births. Am J Perinatol. 2016 Apr 27.

54. Hornik CP, Sherwood AL, Cotten CM, Laughon MM, Clark RH, Smith PB. Daily mortality of infants born at less than 30 weeks' gestation. *Early Hum Dev*. 2016 May;96:27-30.

55. England A*, Wade K, Smith PB, Berezny K, Laughon M; Best Pharmaceuticals for Children Act — Pediatric Trials Network Administrative Core Committee. Optimizing operational efficiencies in early phase trials: The Pediatric Trials Network experience. *Contemp Clin Trials*. 2016 Mar;47:376-82.

56. Lee JH, Smith PB, Quek MB, Laughon MM, Clark RH, Hornik CP. Risk Factors and In-Hospital Outcomes following Tracheostomy in Infants. *J Pediatr*. 2016 Jun;173:39-44.e1

57. Gonzalez D*, Delmore P, Bloom BT, Cotten CM, Poindexter BB, McGowan E, Shattuck K, Bradford KK, Smith PB, Cohen-Wolkowiez M, Morris M, Yin W, Benjamin DK Jr, Laughon MM. Clindamycin Pharmacokinetics and Safety in Preterm and Term Infants. *Antimicrob Agents Chemother*. 2016 Apr 22;60(5):2888-94.

58. Gulack BC*, Laughon MM, Clark RH, Burgess T, Robinson S, Muhammad A, Zhang A, Davis A, Morton R, Chu VH, Arnold CJ, Hornik CP, Smith PB. Enteral Feeding with Human Milk Decreases Time to Discharge in Infants following Gastroschisis Repair. *J Pediatr*. 2015 Dec 15.

59. Kelly MS*, Benjamin DK, Puopolo KM, Laughon MM, Clark RH, Mukhopadhyay S, Benjamin DK Jr, Smith PB, Permar SR. Postnatal Cytomegalovirus Infection and the Risk for Bronchopulmonary Dysplasia. *JAMA Pediatr*. 2015 Dec 7;169 (12):e153785.

60. Askenazi DJ, Morgan C, Goldstein SL, Selewski DT, Moxey-Mims MM, Kimmel PL, Star RA, Higgins R, Laughon M. Strategies to improve the understanding of long-term renal consequences after neonatal acute kidney injury. *Pediatr Res*. 2015 Nov 23.

61. Greenberg RG*, Cochran KM, Smith PB, Edson BS, Schulman J, Lee HC, Govindaswami B, Pantoja A, Hardy D, Curran J, Lin D, Kuo S, Noguchi A, Ittmann P, Duncan S, Gupta M, Picarillo A, Karna P, Cohen M, Giuliano M, Carroll S, Page B, Guzman-Cottrill J, Walker MW, Garland J, Ancona JK, Ellsbury DL, Laughon MM, McCaffrey MJ. Effect of Catheter Dwell Time on Risk of Central Line-Associated Bloodstream Infection in Infants. Pediatrics. 2015 Dec;136 (6):1080-6.

62. Batton B, Li L, Newman NS, Das A, Watterberg KL, Yoder BA, Faix RG, Laughon MM, Stoll BJ, Higgins RD, Walsh MC; Eunice Kennedy Shriver National Institute of Child Health & Human Development Neonatal Research Network. Early blood pressure, antihypotensive therapy and outcomes at 18-22 months' corrected age in extremely preterm infants. Arch Dis Child Fetal Neonatal Ed. 2015 Nov 13.

63. Samiee-Zafarghandy S, van den Anker JN, Laughon MM, Clark RH, Smith PB, Hornik CP. Sildenafil and retinopathy of prematurity risk in very low birth weight infants. J Perinatol. 2016 Feb;36(2):137-40.

64. Lee JH*, Hornik CP, Testoni D, Laughon MM, Cotten CM, Maldonado RS, Belcastro MR, Clark RH, Smith PB. Insulin, Hyperglycemia, and Severe Retinopathy of Prematurity in Extremely Low-Birth-Weight Infants. Am J Perinatol. 2015 Oct 20.

65. Gulack BC*, Laughon MM, Clark RH, Sankar MN, Hornik CP, Brian Smith P. Comparative effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus. Early Hum Dev. 2015 Dec;91(12):725-9.

66. Pineda LC, Hornik CP, Seed PC, Cotten CM, Laughon MM, Bidegain M, Clark RH, Smith PB. Association between positive urine cultures and necrotizing enterocolitis in a large cohort of hospitalized infants. Early Hum Dev. 2015 Jul 27;91 (10):583-586.

67. Zimmerman KO*, Hornik CP, Ku L, Watt K, Laughon MM, Bidegain M, Clark RH, Smith PB. Sedatives and Analgesics Given to Infants in Neonatal Intensive Care Units at the End of Life. J Pediatr. 2015 Aug;167 (2):299-304.e3.

68. Malowitz JR*, Hornik CP, Laughon MM, Testoni D, Cotten CM, Clark RH, Smith PB. Management Practice and Mortality for Infants with Congenital Diaphragmatic Hernia. *Am J Perinatol*. 2015 Feb 25.

69. Autmizguine J*, Hornik CP, Benjamin DK Jr, Laughon MM, Clark RH, Cotten CM, Cohen-Wolkowiez M, Benjamin DK, Smith PB; Best Pharmaceuticals for Children Act—Pediatric Trials Network Administrative Core Committee. Anaerobic antimicrobial therapy after necrotizing enterocolitis in VLBW infants.Pediatrics. 2015 Jan;135 (1):e117-25.

70. Price WA, Aliaga SR, Massie SE, DeWalt DA, Laughon MM, Malcolm WF, Van Meurs K, Klein JM, El-Ferzli G, Magnus BE, Tolleson-Rinehart S. Development and Validation of the Proxy-Reported Pulmonary Outcomes Scale for Premature Infants. *Am J Perinatol.* 2015 Feb 25.

71. Shankaran S, Laptook AR, Pappas A, McDonald SA, Das A, Tyson JE, Poindexter BB, Schibler K, Bell EF, Heyne RJ, Pedroza C, Bara R, Van Meurs KP, Grisby C, Huitema CM, Garg M, Ehrenkranz RA, Shepherd EG, Chalak LF, Hamrick SE, Khan AM, Reynolds AM, Laughon MM, Truog WE, Dysart KC, Carlo WA, Walsh MC, Watterberg KL, Higgins RD; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Effect of depth and duration of cooling on deaths in the NICU among neonates with hypoxic ischemic encephalopathy: a randomized clinical trial. JAMA. 2014 Dec 24-31;312 (24):2629-39.

72. Ambalavanan N, Carlo WA, Wrage LA, Das A, Laughon M, Cotten CM, Kennedy KA, Laptook AR, Shankaran S, Walsh MC, Higgins RD; For the SUPPORT Study Group of the NICHD Neonatal Research Network. PaCO2 in Surfactant, Positive Pressure, and Oxygenation Randomised Trial (SUPPORT). Arch Dis Child Fetal Neonatal Ed. 2014 Nov 25.

73. Dasnadi S*, Aliaga S, Laughon M, Warner DD, Price WA. Factors Influencing the Accuracy of Noninvasive Blood Pressure Measurements in NICU Infants. Am J Perinatol. 2014 Oct 26.

74. Beam KS*, Aliaga S, Ahlfeld SK, Cohen-Wolkowiez M, Smith PB, Laughon MM. A systematic review of randomized controlled trials for the prevention of bronchopulmonary dysplasia in infants. J Perinatol. 2014 Sep;34(9):705-10.

75. Sriram S, Condie J, Schreiber MD, Batton DG, Shah B, Bose C, Laughon M, Van Marter LJ, Allred EN, Leviton A. Early blood gas predictors of bronchopulmonary dysplasia in extremely low gestational age newborns. *Int J Pediatr*. 2014;2014:210218.

76. Corey KM*, Hornik CP, Laughon MM, McHutchison K, Clark RH, Smith PB. Frequency of anomalies and hospital outcomes in infants with gastroschisis and omphalocele. Early Hum Dev. 2014 Aug;90(8):421-4. Laughon MM, Chantala K, Aliaga S, Herring AH, Hornik CP, Hughes R, Clark RH, Smith PB. Diuretic Exposure in Premature Infants from 1997 to 2011. *Am J Perinatol*. 2014 May 6.

77. Beam KS*, Laughon MM, Hornik CP, Cohen-Wolkowiez M, Clark RH, Benjamin DK Jr, Smith PB. Predictors of positive cerebrospinal fluid cultures in infants with bacteremia. *Pediatr Infect Dis J*. 2014 Apr;33(4):360-5.

78. Tremoulet A, Le J, Poindexter B, Sullivan JE, Laughon M, Delmore P, Salgado A, Ian-U Chong S, Melloni C, Gao J, Benjamin DK Jr, Capparelli EV, Cohen-Wolkowiez M; on behalf of the Administrative Core Committee of the Best Pharmaceuticals for Children Act-Pediatric Trials Network. Characterization of the Population Pharmacokinetics of Ampicillin in Neonates Using an Opportunistic Study Design. *Antimicrob Agents Chemother*. 2014 Jun;58(6):3013-3020.

79. Batton B, Li L, Newman NS, Das A, Watterberg KL, Yoder BA, Faix RG, Laughon MM, Stoll BJ, Higgins RD, Walsh MC; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Evolving blood pressure dynamics for extremely preterm infants. *J Perinatol*. 2014 Apr;34(4):301-5.

80. Dobson NR, Patel RM*, Smith PB, Kuehn DR, Clark J, Vyas-Read S, Herring A, Laughon MM, Carlton D, Hunt CE. Trends in Caffeine Use and Association between Clinical Outcomes and Timing of Therapy in Very Low Birth Weight Infants. *J Pediatr*. 2014 May;164(5):992-998.e3.

81. Aliaga S*, Clark RH, Laughon M, Walsh TJ, Hope WW, Benjamin DK, Kaufman D, Arrieta A, Benjamin DK Jr, Smith PB. Changes in the incidence of candidiasis in neonatal intensive care units. *Pediatrics*. 2014 Feb;133(2):236-42.

82. Hsieh EM*, Hornik CP, Clark RH, Laughon MM, Benjamin DK Jr, Smith PB; on Behalf of the Best Pharmaceuticals for Children Act—Pediatric Trials Network. Medication Use in the Neonatal Intensive Care Unit. *Am J Perinatol*. 2013 Dec 17.

83. Onland W, Debray TP, Laughon MM, Miedema M, Cools F, Askie LM, Asselin JM, Calvert SA, Courtney SE, Dani C, Durand DJ, Marlow N, Peacock JL, Pillow JJ, Soll RF, Thome UH, Truffert P, Schreiber MD, Van Reempts P, Vendettuoli V, Vento G, van Kaam AH, Moons KG, Offringa M. Clinical prediction models for bronchopulmonary dysplasia: a systematic review and external validation study. *BMC Pediatr*. 2013 Dec 17;13:207.

84. Laughon MM, Avant D, Tripathi N, Hornik CP, Cohen-Wolkowiez M, Clark RH, Smith PB, Rodriguez W. Drug labeling and exposure in neonates. *JAMA Pediatr*. 2014 Feb;168 (2):130-6.

85. Tunks RD, Barker PC, Benjamin DK Jr, Cohen-Wolkowiez M, Fleming GA, Laughon M, Li JS, Hill KD. Sildenafil Exposure and Hemodynamic Effect After Fontan Surgery. *Pediatr Crit Care Med*. 2013 Nov 6.

86. Hill KD*, Tunks RD, Barker PC, Benjamin DK Jr, Cohen-Wolkowiez M, Fleming GA, Laughon M, Li JS. Sildenafil exposure and hemodynamic effect after stage II single-ventricle surgery. *Pediatr Crit Care Med*. 2013 Jul;14 (6):593-600.

87. Trembath A*, Hornik CP, Clark R, Smith PB, Daniels J, Laughon M; Best Pharmaceuticals for Children Act—Pediatric Trials Network. Comparative effectiveness of surfactant preparations in premature infants. *J Pediatr*. 2013 Oct;163 (4):955-60.e1.

88. Alleman BW, Bell EF, Li L, Dagle JM, Smith PB, Ambalavanan N, Laughon MM, Stoll BJ, Goldberg RN, Carlo WA, Murray JC, Cotten CM, Shankaran S, Walsh MC, Laptook AR, Ellsbury DL, Hale EC, Newman NS, Wallace DD, Das A, Higgins RD; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Individual and center-level factors affecting mortality among extremely low birth weight infants. *Pediatrics*. 2013 Jul;132 (1):e175-84.

89. Batton B, Li L, Newman NS, Das A, Watterberg KL, Yoder BA, Faix RG, Laughon MM, Stoll BJ, Van Meurs KP, Carlo WA, Poindexter BB, Bell EF, Sánchez PJ, Ehrenkranz RA, Goldberg RN, Laptook AR, Kennedy KA, Frantz ID 3rd, Shankaran S, Schibler K, Higgins RD, Walsh MC; Eunice Kennedy Shriver National Institute of Child Health & Human Development Neonatal Research Network. Use of antihypotensive therapies in extremely preterm infants. Pediatrics. 2013 Jun;131(6):e1865-73.

90. Bose CL, Laughon MM, Allred EN, O'Shea TM, Van Marter LJ, Ehrenkranz RA, Fichorova RN, Leviton A; ELGAN Study Investigators. Systemic inflammation associated with mechanical ventilation among extremely preterm infants. Cytokine. 2013 Jan;61(1):315-22.

91. Aliaga SR*, Smith PB, Price WA, Ivester TS, Boggess K, Tolleson-Rinehart S, McCaffrey MJ, Laughon MM. Regional variation in late preterm births in North Carolina. Matern Child Health J. 2013 Jan;17(1):33-41.

92. Bauserman MS*, Laughon MM, Hornik CP, Smith PB, Benjamin DK Jr, Clark RH, Engmann C, Cohen-Wolkowiez M. Group B Streptococcus and Escherichia coli Infections in the Intensive Care Nursery in the Era of Intrapartum Antibiotic Prophylaxis. Pediatr Infect Dis J. 2012 Sep 24.

93. Cohen-Wolkowiez M, Poindexter B, Bidegain M, Weitkamp JH, Schelonka RL, Randolph DA, Ward RM, Wade K, Valencia G, Burchfield D, Arrieta A, Mehta V, Walsh M, Kantak A, Rasmussen M, Sullivan JE, Finer N, Rich W, Brozanski BS, van den Anker J, Blumer J, Laughon M, Watt KM, Kearns GL, Capparelli EV, Martz K, Berezny K, Benjamin DK Jr, Smith PB; Meropenem Study Team. Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections. Clin Infect Dis. 2012 Dec;55(11):1495-502. Downey LC*, Benjamin DK Jr, Clark RH, Watt KM, Hornik CP, Laughon MM, Cohen-Wolkowiez M, Smith PB. Urinary tract infection concordance with positive blood and cerebrospinal fluid cultures in the neonatal intensive care unit. J Perinatol. 2012 Aug 30.

94. Downey LC*, Benjamin DK Jr, Clark RH, Watt KM, Hornik CP, Laughon MM, Cohen-Wolkowiez M, Smith PB. Urinary tract infection concordance with positive blood and cerebrospinal fluid cultures in the neonatal intensive care unit. *J Perinatol*. 2012 Aug 30. PMCID: 3549035.

95. Turner K*, Manzoni P, Benjamin DK, Cohen-Wolkowiez M, Smith PB, Laughon MM. Fluconazole pharmacokinetics and safety in premature infants. Curr Med Chem. 2012;19(27):4617-20.

96. Smith PB, Ambalavanan N, Li L, Cotten CM, Laughon M, Walsh MC, Das A, Bell EF, Carlo WA, Stoll BJ, Shankaran S, Laptook AR, Higgins RD, Goldberg RN; Generic Database Subcommittee; Eunice Kennedy Shriver National Institute of Child Health Human Development Neonatal Research Network. Approach to infants born at 22 to 24 weeks' gestation: relationship to outcomes of more-mature infants. Pediatrics. 2012 Jun;129(6):e1508-16.

97. Batton BJ, Li L, Newman NS, Das A, Watterberg KL, Yoder BA, Faix RG, Laughon MM, Van Meurs KP, Carlo WA, Higgins RD, Walsh MC; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Feasibility study of early blood pressure management in extremely preterm infants. J Pediatr. 2012 Jul;161(1):65-9.e1.

98. Watt KM*, Massaro MM, Smith B, Cohen-Wolkowiez M, Benjamin DK Jr, Laughon MM. Pharmacokinetics of Moxifloxacin in an Infant With Mycoplasma hominis Meningitis. Pediatr Infect Dis J. 2011 Oct 19.

99. Laughon MM, Benjamin DK Jr, Capparelli EV, Kearns GL, Berezny K, Paul IM, Wade K, Barrett J, Smith PB, Cohen-Wolkowiez M. Innovative clinical trial design for pediatric therapeutics. Expert Rev Clin Pharmacol. 2011 Sep;4(5):643-652.

100. Massie SE, Tolleson-Rinehart S, DeWalt DA, Laughon MM, Powell LM, Price WA. Development of a proxy-reported pulmonary outcome scale for preterm infants with bronchopulmonary dysplasia. Health Qual Life Outcomes. 2011 Jul 26;9:55.

101. Jean-Baptiste N*, Benjamin DK Jr, Cohen-Wolkowiez M, Fowler VG Jr, Laughon M, Clark RH, Smith PB. Coagulase-negative staphylococcal infections in the neonatal intensive care unit. *Infect Control Hosp Epidemiol*. 2011 Jul;32(7):679-86.

102. Laughon M, Bose C, Allred EN, O'Shea TM, Ehrenkranz RA, Van Marter LJ, Leviton A; for the ELGAN Study Investigators. Patterns of blood protein concentrations of ELGANs classified by three patterns of respiratory disease in the first two postnatal weeks. *Pediatr Res*. 2011 Jun 3. PMCID: PMC309030.

103. Clark RH, Gordon P, Walker WM, Laughon M, Smith PB, Spitzer AR. Characteristics of patients who die of necrotizing enterocolitis. *J Perinatol*. 2011 May 19.

104. Laughon MM, Langer JC, Bose CL, Smith PB, Ambalavanan N, Kennedy KA, Stoll BJ, Buchter S, Laptook AR, Ehrenkranz RA, Cotten CM, Wilson-Costello DE, Shankaran S, Van Meurs KP, Davis AS, Gantz MG, Finer NN, Yoder BA, Faix RG, Carlo WA, Schibler KR, Newman NS, Rich W, Das A, Higgins RD, Walsh MC; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Prediction of bronchopulmonary dysplasia by postnatal age in extremely premature infants. *Am J Respir Crit Care Med*. 2011 Jun 15;183(12):1715-22. PMCID pending

    104.1.1.1. NOTE: an electronic, free version of the NICHD Neonatal Research Network bronchopulmonary dysplasia estimator is available at https://neonatal.rti.org/index.cfm?fuseaction=BPDCalculator.start; this has been accessed >50,000 times

105. Laughon M, Bose C, Allred EN, O'Shea TM, Ehrenkranz RA, Van Marter LJ, Leviton A; for the ELGAN Study Investigators. Antecedents of chronic lung disease following three patterns of early respiratory disease in preterm infants. *Arch Dis Child Fetal Neonatal Ed*. 2011 Mar;96(2):F114-F120.

106. Van Marter LJ, Kuban KC, Allred E, Bose C, Dammann O, O'Shea M, Laughon M, Ehrenkranz RA, Schreiber MD, Karna P, Leviton A; ELGAN Study Investigators. Does bronchopulmonary dysplasia contribute to the occurrence of cerebral palsy among infants born before 28 weeks of gestation? *Arch Dis Child Fetal Neonatal Ed*. 2011 Jan;96(1):F20-9.

107. Logan JW*, O'Shea TM, Allred EN, Laughon MM, Bose CL, Dammann O, Batton DG, Kuban KC, Paneth N, Leviton A. Early postnatal hypotension is not associated with indicators of white matter damage or cerebral palsy in extremely low gestational age newborns. *J Perinatol*. 2011 Jan 27.

108. Greenberg RG, Benjamin DK Jr, Cohen-Wolkowiez M, Clark RH, Cotten CM, Laughon M, Smith PB. Repeat lumbar punctures in infants with meningitis in the neonatal intensive care unit. *J Perinatol*. 2010 Dec 16.

109. Courtwright AM*, Laughon MM, Doron MW. Length of life and treatment intensity in infants diagnosed prenatally or postnatally with congenital anomalies considered to be lethal. *J Perinatol.* 2010 Dec 16.

110. Bose C, Laughon M, Allred EN, Van Marter LJ, O'shea TM, Ehrenkranz RA, Fichorova R, Leviton A; for the ELGAN Study Investigators. Blood protein concentrations in the first two postnatal weeks that predict bronchopulmonary dysplasia among infants born before the 28th week of gestation. *Pediatr Res.* 2010 Dec 9.

111. Logan JW, O'Shea TM, Allred EN, Laughon MM, Bose CL, Dammann O, Batton DG, Engelke SC, Leviton A; for the ELGAN Study Investigators. Early postnatal hypotension and developmental delay at 24 months of age among extremely low gestational age newborns. *Arch Dis Child Fetal Neonatal Ed*. 2010 Dec 7.

112. Laughon M, Smith PB, Bose C. Prevention of Chronic Lung Disease. *Archives of Diseases in Childhood: Neonatal-Perinatal Edition* Dec;14(6):374-82. Epub 2009 Sep 6.

113. Bose C, Van Marter LJ, Laughon M, O'Shea M, Allred EN, Karna P, Ehrenkranz RA, Boggess K, Leviton A. Fetal growth restriction is followed by an increased risk of chronic lung disease among infants born before the 28th week of gestation. *Pediatrics*. 2009 Aug 17.

114. Laughon M, O'Shea TM, Allred EN, Bose C, Kuban K, Van Marter LJ, Ehrenkranz RA, Leviton A. Chronic lung disease and the risk of developmental delay at two years of age in children without severe gross motor delays born before 28 weeks postmenstrual age. *Pediatrics*. 2009 Jul 20.

115. Troy R*, Doron M, Laughon M, Tolleson-Rinehart S, Price W. Comparison of Non-Invasive and Central Arterial Blood Pressure Measurements in Extremely Low Birth Weight Infants. *Journal of Perinatology*, 2009 Nov;29(11):744-9.

116. Laughon M, Allred EN, Bose C, O'Shea TM, Van Marter LJ, Ehrenkranz RA, Leviton A. Patterns of respiratory disease during the first 2 postnatal weeks in extremely premature infants. *Pediatrics*. 2009 Apr;123(4):1124-31.

117. Laughon M, Bose C, Moya F, Aschner J, Donn SM, Morabito C, Cummings JJ, Segal R, Guardia C, Liu G. A pilot randomized, controlled trial of later treatment with a Peptide-containing, synthetic surfactant for the prevention of bronchopulmonary dysplasia. *Pediatrics*. 2009 Jan;123(1):89-96.

118. Rojas MA, Lozano JM, Rojas MX, Laughon M, Bose CL, Rondon MA, Charry L, Bastidas JA, Perez LA, Rojas C, Ovalle O, Celis LA, Garcia-Harker J, Jaramillo ML. Very early surfactant without mandatory ventilation in premature infants treated with early continuous positive airway pressure: a randomized, controlled trial. *Pediatrics*. 2009 Jan;123(1):137-42.

119. South AP*, Marshall DD, Bose CL, Laughon M. Growth and neurodevelopment at 16 to 24 months of age for infants born with gastroschisis. *J Perinatol*. 2008 Jul 10.

120. Herrman K*, Bose C, Lewis K, Laughon M. Spontaneous Closure of the Patent Ductus Arteriosus in Very Low Birth Weight Infants Following Discharge from the Neonatal Unit. *Arch Dis Ch*. 2008 May 1.

121. Laughon M, Bose C, Allred E, O'Shea TM, Van Marter LJ, Bednarek F, Leviton A. Factors associated with treatment for hypotension in extremely low gestational age newborns during the first postnatal week. Pediatrics. 2007 Feb;119(2):273-80.

122. Laughon M, Bose C, Clark R. Treatment strategies to prevent or close a patent ductus arteriosus in preterm infants and outcomes. *J Perinatol*. 2007 Mar;27(3):164-70.

123. Raval MV*, Laughon M, Bose CL, Phillips JD. Patent ductus arteriosus ligation in premature infants: who really benefits, and at what cost? *J Pediatr Surg*. 2007 Jan;42(1):69-75; discussion.

124. Eng W*, LeGrys VA, Schechter MS, Laughon M, Barker PM. Sweat-testing in preterm and full-term infants less than 6 weeks of age. *Pediatr Pulmonol*. 2005 Jul;40(1):64-7.

125. Laughon M, Meyer R, Bose C, Wall A, Otero E, Heerens A, Clark R. Rising birth prevalence of gastroschisis. *J Perinatol*. 2003 Jun;23(4):291-3.

126. Mohr JJ, Randolph GD, Laughon M, Schaff E. Integrating improvement competencies into residency education: a pilot project from a pediatric continuity clinic. *Ambul Pediatr*. 2003 May-Jun;3(3):131-6.

127. Faulkner DM, Sutton ST, Hesford JD, Faulkner BC, Major DA, Hellewell TB, Laughon M, Rodeheaver GT, Edlich RF. A new stable pluronic F68 gel carrier for antibiotics in contaminated wound treatment. *Am J Emerg Med*. 1997 Jan;15(1):20-4.

128. Zemmel NJ, Park SM, Schweitzer J, O'Keefe JS, Laughon M, Edlich RF. Status of Voicetype Dictation for Windows for the emergency physician. *J Emerg Med*. 1996 Jul-Aug;14(4):511-5.

129. Gerard MW, Laughon M, Colley JL, 3rd, Glasheen WP, Hoard MA, Edlich RF. Trends in temporomandibular joint surgery. *Med Prog Technol*. 1996;21(4):171-5.

Other Peer Reviewed Articles

1. Steinhorn R, Davis JM, Göpel W, Jobe A, Abman S, Laughon M, Bancalari E, Aschner J, Ballard R, Greenough A, Storari L, Thomson M, Ariagno RL, Fabbri L, Turner MA; International Neonatal Consortium. Chronic Pulmonary Insufficiency of Prematurity: Developing Optimal Endpoints for Drug Development.J Pediatr. 2017 Dec;191:15-21.e1.

2. Johnson JK*, Laughon MM. Antimicrobial Agent Dosing in Infants. Clin Ther. 2016 Sep;38(9):1948-60.

3. Perez KM*, Laughon M. Sildenafil in Term and Premature Infants: A Systematic Review. Clin Ther. 2015 Nov 1;37(11):2598-2607.e1.

4. Ericson JE*, Laughon MM. Chorioamnionitis: Implications for the Neonate. Clin Perinatol. 2015 Mar;42(1):155-165.

5. Perez KM*, Laughon MM. What is new for patent ductus arteriosus management in premature infants in 2015? Curr Opin Pediatr. 2015 Feb 13.

6. Smith PB, Laughon MM. Dissemination of Information from Pediatric Studies Conducted under BPCA and PREA. *National Academies of Science Institute of Medicine*, Appendix B 2013.

7. Trembath A*, Laughon MM. Predictors of bronchopulmonary dysplasia. Clin Perinatol. 2012 Sep;39(3):585-601. doi: 10.1016/j.clp.2012.06.014.

8. Laughon M, Bose C, Benitz WE. Patent ductus arteriosus management: what are the next steps? J Pediatr. 2010 Sep;157(3):355-7. Epub 2010 Jun 30.

9. Bose CL, Laughon M, Dammann CE. Bronchopulmonary dysplasia and inflammatory biomarkers in the premature neonate. *Arch Dis Child Fetal Neonatal Ed*. 2008;93(6):F455-61.

10. Bose CL, Laughon M. Patent ductus arteriosus: lack of evidence for common treatments. *Arch Dis Child Fetal Neonatal Ed*. 2007 Nov;92(6):F498-502.

11. Bose CL, Laughon M. Treatment to prevent patency of the ductus arteriosus: beneficial or harmful? *J Pediatr*. 2006 Jun;148(6):713-4.

12. Laughon M, Simmons MA, Bose CL. Patency of the ductus arteriosus in the premature infant: is it pathologic? Should it be treated? *Curr Opin Pediatr*. 2004 Apr;16(2):146-51.